Literature DB >> 12495477

Impact of the p53 status of the tumor cells on the effect of reactor neutron beam irradiation, with emphasis on the response of intratumor quiescent cells.

Shin-ichiro Masunaga1, Koji Ono, Akihisa Takahashi, Yoshinori Sakurai, Ken Ohnishi, Toru Kobayashi, Yuko Kinashi, Masao Takagaki, Takeo Ohnishi.   

Abstract

Human head and neck squamous cell carcinoma cells transfected with mutant p53 (SAS/mp53) or with neo vector as a control (SAS/neo) were inoculated subcutaneously into both the hind legs of Balb/cA nude mice. Tumor-bearing mice received 5-bromo-2'-deoxyuridine (BrdU) continuously to label all proliferating (P) cells in the tumors. After administration of sodium borocaptate-10B (BSH) or p-boronophenylalanine-10B (BPA), the tumors were irradiated with neutron beams. The tumors not treated with 10B-compound were irradiated with neutron beams or gamma-rays. The tumors were then excised, minced and trypsinized. The tumor cell suspensions thus obtained were incubated with a cytokinesis blocker, and the micronucleus (MN) frequency in cells without BrdU labeling (=quiescent (Q) cells) was determined using immunofluorescence staining for BrdU. Meanwhile, 6 h after irradiation, tumor cell suspensions obtained in the same manner were used for determining the frequency of apoptosis in Q cells. The MN and apoptosis frequencies in total (P+Q) tumor cells were determined from the tumors that were not pretreated with BrdU. Without 10B-carriers, in both tumors, the relative biological effectiveness of neutrons was greater in Q cells than in total cells, and larger for low than high cadmium ratio neutrons. With 10B-carriers, the sensitivity was increased for each cell population, especially for total cells. BPA increased both frequencies for total cells more than BSH. Nevertheless, the sensitivity of Q cells treated with BPA was lower than that of BSH-treated Q cells. These sensitization patterns in combination with 10B-carriers were clearer in SAS/neo than in SAS/mp53 tumors. The p53 status of the tumor cells had the potential to affect the response to reactor neutron beam irradiation following 10B-carrier administration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12495477      PMCID: PMC5926926          DOI: 10.1111/j.1349-7006.2002.tb01246.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  30 in total

1.  Production of chromosome aberrations, micronuclei, and sister-chromatid exchanges by 24-keV epithermal neutrons in human G0 lymphocytes.

Authors:  S Z Aghamohammadi; D T Goodhead; J R Savage
Journal:  Mutat Res       Date:  1989-04       Impact factor: 2.433

2.  p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes.

Authors:  C Caelles; A Helmberg; M Karin
Journal:  Nature       Date:  1994-07-21       Impact factor: 49.962

3.  Contribution of protein kinase C to p53-dependent WAF1 induction pathway after heat treatment in human glioblastoma cell lines.

Authors:  K Ohnishi; X Wang; A Takahashi; T Ohnishi
Journal:  Exp Cell Res       Date:  1998-02-01       Impact factor: 3.905

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity.

Authors:  J A Coderre; A D Chanana; D D Joel; E H Elowitz; P L Micca; M M Nawrocky; M Chadha; J O Gebbers; M Shady; N S Peress; D N Slatkin
Journal:  Radiat Res       Date:  1998-02       Impact factor: 2.841

Review 6.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

Authors:  J M Brown; A J Giaccia
Journal:  Cancer Res       Date:  1998-04-01       Impact factor: 12.701

Review 7.  The radiation biology of boron neutron capture therapy.

Authors:  J A Coderre; G M Morris
Journal:  Radiat Res       Date:  1999-01       Impact factor: 2.841

8.  Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy.

Authors:  K Ono; S I Masunaga; Y Kinashi; M Takagaki; M Akaboshi; T Kobayashi; K Akuta
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-15       Impact factor: 7.038

9.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

Authors:  V Dulić; W K Kaufmann; S J Wilson; T D Tlsty; E Lees; J W Harper; S J Elledge; S I Reed
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

10.  Cell survival measurements in an argon, aluminium and sulphur filtered neutron beam: a comparison with 24 keV neutrons and relevance to boron neutron capture therapy.

Authors:  A J Mill; G R Morgan; S M Newman
Journal:  Br J Radiol       Date:  1994-10       Impact factor: 3.039

View more
  7 in total

1.  Abscopal effect of boron neutron capture therapy (BNCT): proof of principle in an experimental model of colon cancer.

Authors:  Verónica A Trivillin; Emiliano C C Pozzi; Lucas L Colombo; Silvia I Thorp; Marcela A Garabalino; Andrea Monti Hughes; Sara J González; Rubén O Farías; Paula Curotto; Gustavo A Santa Cruz; Daniel G Carando; Amanda E Schwint
Journal:  Radiat Environ Biophys       Date:  2017-08-08       Impact factor: 1.925

2.  Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax.

Authors:  Peng Wang; Haining Zhen; Xinbiao Jiang; Wei Zhang; Xin Cheng; Geng Guo; Xinggang Mao; Xiang Zhang
Journal:  BMC Cancer       Date:  2010-12-02       Impact factor: 4.430

3.  An attempt to improve the therapeutic effect of boron neutron capture therapy using commonly employed 10B-carriers based on analytical studies on the correlation among quiescent tumor cell characteristics, tumor heterogeneity and cancer stemness.

Authors:  Shin-Ichiro Masunaga; Yu Sanada; Keizo Tano; Yoshinori Sakurai; Hiroki Tanaka; Takushi Takata; Minoru Suzuki; Koji Ono
Journal:  J Radiat Res       Date:  2020-11-16       Impact factor: 2.724

4.  Role of p53 mutation in the effect of boron neutron capture therapy on oral squamous cell carcinoma.

Authors:  Yusei Fujita; Itsuro Kato; Soichi Iwai; Koji Ono; Minoru Suzuki; Yoshinori Sakurai; Ken Ohnishi; Takeo Ohnishi; Yoshiaki Yura
Journal:  Radiat Oncol       Date:  2009-12-11       Impact factor: 3.481

5.  Apoptosis through Bcl-2/Bax and cleaved caspase up-regulation in melanoma treated by boron neutron capture therapy.

Authors:  Fernanda Faião-Flores; Paulo Rogério Pinto Coelho; João Dias Toledo Arruda-Neto; Silvya Stuchi Maria-Engler; Manoela Tiago; Vera Luiza Capelozzi; Ricardo Rodrigues Giorgi; Durvanei Augusto Maria
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

6.  Sonoporation as an enhancing method for boron neutron capture therapy for squamous cell carcinomas.

Authors:  Naofumi Yamatomo; Takaki Iwagami; Itsuro Kato; Shin-Ichiro Masunaga; Yoshinori Sakurai; Soichi Iwai; Mitsuhiro Nakazawa; Koji Ono; Yoshiaki Yura
Journal:  Radiat Oncol       Date:  2013-12-02       Impact factor: 3.481

7.  Extracellular Release of HMGB1 as an Early Potential Biomarker for the Therapeutic Response in a Xenograft Model of Boron Neutron Capture Therapy.

Authors:  Shoji Imamichi; Lichao Chen; Tasuku Ito; Ying Tong; Takae Onodera; Yuka Sasaki; Satoshi Nakamura; PierLuigi Mauri; Yu Sanada; Hiroshi Igaki; Yasufumi Murakami; Minoru Suzuki; Jun Itami; Shinichiro Masunaga; Mitsuko Masutani
Journal:  Biology (Basel)       Date:  2022-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.